Nyxoah price target lowered to $16 from $17 at Cantor Fitzgerald

Cantor Fitzgerald lowered the firm’s price target on Nyxoah to $16 from $17 and keeps an Overweight rating on the shares. Nyxoah reported Q2 revenue of $800,000, representing a year over year decline of 30%, driven by operations in Germany, which accounted for almost all the revenue, the analyst tells investors in a research note. All eyes remain on FDA approval for Genio, and the company has made several key hires to support the launch in late-2024 and early-2025, including a COO and sales leader, the firm says.